CAPR ran up 439% in December after releasing positive Phase 3 results for Deramiocel, a treatment for Duchenne muscular dystrophy. The study met primary and secondary endpoints, showing it slowed upper limb functional decline by 54% and heart function decline by 91%. They plan to submit this data to the FDA to address a rejection letter from July. If approved, launch could happen in 2026. They also raised $150M in a stock offering and have a distribution deal with Nippon Shinyaku worth up to $1.5B in milestones. Just note that approval isn't guaranteed since they are responding to a prior Complete Response Letter.